Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
08 jan 2015 - 07:38
Statutaire naam
Galapagos NV
Titel
Galapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patients
Bericht
Mechelen, Belgium; 8 January 2015 - Galapagos NV (Euronext: GLPG) announced today it has initiated a Phase 2 Proof-of-Concept study in ulcerative colitis with GPR84 inhibitor GLPG1205, a potential novel treatment for Inflammatory Bowel Diseases. GLPG1205 arises from Galapagos' target discovery platform and is fully proprietary to Galapagos.
GLPG1205 ('1205) inhibits GPR84, a novel mechanism of action developed by Galapagos for Inflammatory Bowel Diseases (IBD). Galapagos has shown that GPR84 plays a key role in IBD and that '1205 is a selective inhibitor of GPR84 and very effective in pre-clinical models for IBD. In Phase 1 studies, '1205 showed good safety, full blockage of GPR84, and favorable drug-like properties. The first patients in this double-blind, placebo controlled study will initiate their treatment this week.
Datum laatste update: 08 februari 2025